SCHEMBL25567992

SCHEMBL25567992

CC(C)CCN1CCC(OC(=O)NC(C)C)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.40
CHRM3 P20309 6/20 0.39
BCHE P06276 1/20 0.39
NAMPT P43490 1/20 0.39
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
PKM P14618 1/20 0.39
NFKB1 P19838 1/20 0.39
THPO P40225 1/20 0.39
HIF1A Q16665 1/20 0.39
CARM1 Q86X55 1/20 0.39
PRMT6 Q96LA8 1/20 0.39
DPP4 P27487 2/20 0.38
ALDH1A1 P00352 2/20 0.38
MEN1 O00255 1/20 0.38
GMNN O75496 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22892755 0.87 OPRL1 (0.42) MAOBCHRM3BCHENAMPTTP53
SCHEMBL27727639 0.83 MAOB (0.39) MAOBCHRM3BCHENAMPTTP53
SCHEMBL20069009 0.81 CHRM3 (0.46) CHRM3CYP3A4DPP4ALDH1A1MEN1
SCHEMBL13519661 0.78 ARG1 (0.41) CHRM3NAMPTTP53CYP1A2CYP3A4
SCHEMBL25568041 0.77 MEN1 (0.54) MEN1LMNAKMT2AARG1ARG2
SCHEMBL14501550 0.77 EPHX1 (0.47) CYP3A4DPP4EPHX1TSHR
SCHEMBL21652040 0.76 CYP3A4 (0.40) MAOBCHRM3BCHECYP3A4DPP4
SCHEMBL20147696 0.76 HRH3 (0.42) MAOBCYP3A4DPP4EPHX1TSHR
SCHEMBL28249234 0.76 NTMT1 (0.37) MAOBCHRM3BCHENAMPTCYP2D6
SCHEMBL13519654 0.75 ALDH1A1 (0.45) CHRM3TP53CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167105-A1 BCL-2 PROTEIN INHIBITORS RECURIUM IP HOLDINGS, LLC 2023-06-01 US disclosed
US-20230167105-A1 BCL-2 PROTEIN INHIBITORS RECURIUM IP HOLDINGS, LLC 2023-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167105-A1 BCL-2 PROTEIN INHIBITORS BCL2, BCL2L1, BCL2L2 MAOB 3317/4885CHRM3 4882/4885BCHE 4288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.